Potent and Persistent Antibody Response in COVID-19 Recovered Patients

Xiaodong Tian; Xiaodong Tian; Ling Liu; Ling Liu; Wenguo Jiang; He Zhang; Wenjun Liu; Wenjun Liu; Wenjun Liu; Wenjun Liu; Wenjun Liu; Jing Li; Jing Li

doi:10.3389/fimmu.2021.659041

Frontiers in Immunology (May 2021)

Potent and Persistent Antibody Response in COVID-19 Recovered Patients

Xiaodong Tian,
Xiaodong Tian,
Ling Liu,
Ling Liu,
Wenguo Jiang,
He Zhang,
Wenjun Liu,
Wenjun Liu,
Wenjun Liu,
Wenjun Liu,
Wenjun Liu,
Jing Li,
Jing Li

Affiliations

Xiaodong Tian: CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
Xiaodong Tian: School of Life Sciences, University of Science and Technology of China, Hefei, China
Ling Liu: CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
Ling Liu: Institutes of Physical Science and Information Technology, Anhui University, Hefei, China
Wenguo Jiang: Jining Center for Disease Control and Prevention, Shandong, China
He Zhang: CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
Wenjun Liu: CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
Wenjun Liu: School of Life Sciences, University of Science and Technology of China, Hefei, China
Wenjun Liu: Institutes of Physical Science and Information Technology, Anhui University, Hefei, China
Wenjun Liu: Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China
Wenjun Liu: Institute of Microbiology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Beijing, China
Jing Li: CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
Jing Li: Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China

DOI: https://doi.org/10.3389/fimmu.2021.659041
Journal volume & issue: Vol. 12

Abstract

Read online

SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Virus-specific antibodies can be detected in infected patients approximately two weeks after symptom onset. In this study, we set up ELISA technology coating with purified SARS-CoV-2 S and N proteins to study the antibody response of 484 serum samples. We established a surrogate viral inhibition assay using SARS-CoV-2 S protein pseudovirus system to determine the neutralization potency of collected serum samples. Here, we report robust antibody responses to SARS-CoV-2 in 484 recovered patients varying from 154 to 193 days, with 92% of recovered patients displaying a positive virus-specific spike glycoprotein IgG (s-IgG) response, while the ratio of positive spike glycoprotein IgM (s-IgM) reached 63%. Furthermore, moderate to potent neutralization activities were also observed in 62% of patients, correlating significantly with s-IgG response. This study strongly supports the long-term presence of antibodies in recovered patients against SARS-CoV-2, although all serum samples were collected from individuals with mild or moderate symptoms.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords